Table 5.
Comparison of the Treatment Lines and Agents of CLL Patients with or without SPC
| CLL patients without SPC (n=502) | CLL patients with SPC (n=51) | Overall (n=553) | p.value | |||||
|---|---|---|---|---|---|---|---|---|
| No | % | No | % | No | % | |||
| The number of treatment lines | 0 | 392 | 78.09 | 33 | 64.71 | 425 | 76.86 | 0.2 |
| 1 | 72 | 14.34 | 13 | 25.49 | 85 | 15.37 | ||
| 2 | 24 | 4.78 | 4 | 7.84 | 28 | 5.06 | ||
| 3 | 12 | 2.39 | 1 | 1.96 | 13 | 2.35 | ||
| 4 | 2 | 0.40 | 0 | 0 | 2 | 0.36 | ||
| Drugs | Fludarabine | 65 | 12.95 | 12 | 23.53 | 77 | 13.92 | 0.027 |
| Bendamustine | 30 | 5.98 | 1 | 1.96 | 31 | 5.60 | ||
| Chlorambucil | 32 | 6.37 | 3 | 5.88 | 35 | 6.33 | ||
| Ibrutinib | 20 | 3.98 | 2 | 3.92 | 22 | 3.97 | ||
| Venetoclax | 2 | 0.39 | 0 | 0 | 2 | 0.36 | ||
| Monoclonal Antibody* | 93 | 18.52 | 16 | 31.37 | 109 | 19.71 | ||
*(Rituximab, Alemtuzumab, Obinutuzumab)